<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092647</url>
  </required_header>
  <id_info>
    <org_study_id>SIMR_onc19_IIS_D'Andre_Ashwaga</org_study_id>
    <nct_id>NCT04092647</nct_id>
  </id_info>
  <brief_title>Ashwagandha for Cognitive Dysfunction</brief_title>
  <official_title>A Randomized Placebo-controlled Trial of Ashwagandha (Withania Somnifera) for Cognitive Dysfunction Associated With Breast Cancer Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutter Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutter Health</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 1:1 randomized double blinded placebo controlled trial. The primary objective is to
      determine if ashwagandha can improve cognitive dysfunction when compared with placebo in
      patients undergoing chemotherapy for breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are eligible if they are undergoing chemotherapy for breast cancer, are scheduled to
      receive at least four rounds, and state that they notice thinking or memory problems during
      their first two cycles of chemotherapy. Patients will be given FACT-Cog PCI (Version 3).
      Patients that score less than 63, a score that reflects moderate to severe cognitive
      problems, are confirmed eligible. Subjects will be randomized 1:1 in blocks of 4.

      Treatment will begin at the start of the third cycle of chemotherapy and continue for 9
      weeks. Thyroid hormone testing will be conducted at baseline and at the end of week 6 for
      patients with a history of thyroid disease.

      Patients will receive ashwagandha 500 mg po BID or placebo. The investigators and
      participants will be blinded to group assignment.

      Endpoint testing including the FACT-Cog PCI and total score, Hopkins verbal learning test,
      trail making test (abstraction and executive function), and Mini Mental Status Exam (MMSE)
      will be administered at baseline and after 9 weeks of treatment. Six months after stopping
      the study, patients will receive a link to a REDCap database to complete the FACT-Cog and
      state whether they used ashwagandha once they completed the study.

      Active study participation will be for 9 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a 1:1 randomized double blinded placebo controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FACT-Cog PCI</measure>
    <time_frame>9 weeks</time_frame>
    <description>The Functional Assessment of Cancer Therapy - Cognition (FACT-Cog) is a 37-item questionnaire designed to assess cognitive complaints in patients with cancer. The Perceived Cognitive Impairment (PCI) subscale consists of 20 items designed to measure perceived impairment in quality of life. Scores range from 0-72 where higher scores indicate less impairment and better quality of life.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ashwagandha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ashwagandha</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ashwagandha</intervention_name>
    <description>Ashwagandha 500 mg po BID</description>
    <arm_group_label>ashwagandha</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 500 mg po BID</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years and older

          2. English speaking

          3. No prior history of chemotherapy

          4. Diagnosed with any stage of breast cancer and scheduled to undergo at least 4 cycles
             of chemotherapy

          5. Self-reported memory loss, attention, visual-spatial functioning, reasoning, or
             information processing or cognitive changes in the first 2 cycles of chemotherapy and
             score &lt; 63 on the FACT-Cog PCI

          6. Able to follow instructions for testing and comply with testing

          7. Able to swallow pills

        Exclusion Criteria:

          1. History of pre-existing dementia, untreated depression, psychiatric disorder, prior
             brain radiation or brain injury

          2. Brain metastasis

          3. Taking any drugs daily that would alter cognition;

          4. Currently taking hypoglycemic medications

          5. History of substance abuse

          6. No current or recent diagnosis of stomach ulcer or gastritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy D'Andre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol Parise, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sutter Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lenell Ordanza</last_name>
    <phone>9168874745</phone>
    <email>ordanzl@sutterhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Parise, PhD</last_name>
    <phone>9168874744</phone>
    <email>parisec@sutterhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stacy D'Andre, MD</last_name>
      <phone>916-453-3300</phone>
      <email>dandrs1@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Stacy D'Andre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol. 2017 Feb 10;35(5):506-514. doi: 10.1200/JCO.2016.68.5826. Epub 2016 Dec 28.</citation>
    <PMID>28029304</PMID>
  </reference>
  <reference>
    <citation>Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002 Jan 15;20(2):485-93.</citation>
    <PMID>11786578</PMID>
  </reference>
  <reference>
    <citation>Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007 Jan 1;109(1):146-56.</citation>
    <PMID>17131349</PMID>
  </reference>
  <reference>
    <citation>Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010 Jul 15;116(14):3348-56. doi: 10.1002/cncr.25098.</citation>
    <PMID>20564075</PMID>
  </reference>
  <reference>
    <citation>Hardy SJ, Krull KR, Wefel JS, Janelsins M. Cognitive Changes in Cancer Survivors. Am Soc Clin Oncol Educ Book. 2018 May 23;38:795-806. doi: 10.1200/EDBK_201179. Review.</citation>
    <PMID>30231372</PMID>
  </reference>
  <reference>
    <citation>Lawrence JA, Griffin L, Balcueva EP, Groteluschen DL, Samuel TA, Lesser GJ, Naughton MJ, Case LD, Shaw EG, Rapp SR. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv. 2016 Feb;10(1):176-84. doi: 10.1007/s11764-015-0463-x. Epub 2015 Jul 1.</citation>
    <PMID>26130292</PMID>
  </reference>
  <reference>
    <citation>Tong T, Pei C, Chen J, Lv Q, Zhang F, Cheng Z. Efficacy of Acupuncture Therapy for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients. Med Sci Monit. 2018 May 8 [revised 2018 Jan 1];24:2919-2927. doi: 10.12659/MSM.909712.</citation>
    <PMID>29735975</PMID>
  </reference>
  <reference>
    <citation>Kaur T, Kaur G. Withania somnifera as a potential candidate to ameliorate high fat diet-induced anxiety and neuroinflammation. J Neuroinflammation. 2017 Oct 12;14(1):201. doi: 10.1186/s12974-017-0975-6.</citation>
    <PMID>29025435</PMID>
  </reference>
  <reference>
    <citation>Kuboyama T, Tohda C, Komatsu K. Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. Biol Pharm Bull. 2014;37(6):892-7. Review.</citation>
    <PMID>24882401</PMID>
  </reference>
  <reference>
    <citation>Gupta M, Kaur G. Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study. J Neuroinflammation. 2016 Aug 22;13(1):193. doi: 10.1186/s12974-016-0650-3.</citation>
    <PMID>27550017</PMID>
  </reference>
  <reference>
    <citation>Pingali U, Pilli R, Fatima N. Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacognosy Res. 2014 Jan;6(1):12-8. doi: 10.4103/0974-8490.122912.</citation>
    <PMID>24497737</PMID>
  </reference>
  <reference>
    <citation>Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry. 2013 Nov;74(11):1076-83. doi: 10.4088/JCP.13m08413.</citation>
    <PMID>24330893</PMID>
  </reference>
  <reference>
    <citation>Choudhary D, Bhattacharyya S, Bose S. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions. J Diet Suppl. 2017 Nov 2;14(6):599-612. doi: 10.1080/19390211.2017.1284970. Epub 2017 Feb 21.</citation>
    <PMID>28471731</PMID>
  </reference>
  <reference>
    <citation>Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013 Jul;12(4):312-22. doi: 10.1177/1534735412464551. Epub 2012 Nov 9.</citation>
    <PMID>23142798</PMID>
  </reference>
  <reference>
    <citation>Panda S, Kar A. Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. J Pharm Pharmacol. 1998 Sep;50(9):1065-8.</citation>
    <PMID>9811169</PMID>
  </reference>
  <reference>
    <citation>Panda S, Kar A. Withania somnifera and Bauhinia purpurea in the regulation of circulating thyroid hormone concentrations in female mice. J Ethnopharmacol. 1999 Nov 1;67(2):233-9.</citation>
    <PMID>10619390</PMID>
  </reference>
  <reference>
    <citation>Sharma AK, Basu I, Singh S. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial. J Altern Complement Med. 2018 Mar;24(3):243-248. doi: 10.1089/acm.2017.0183. Epub 2017 Aug 22.</citation>
    <PMID>28829155</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutter Health</investigator_affiliation>
    <investigator_full_name>Stacy D'Andre, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ashwagandha</keyword>
  <keyword>cognitive dysfunction</keyword>
  <keyword>breast cancer chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

